

# Visiting Professors

A case-based discussion on the management of non-Hodgkin lymphomas and chronic lymphocytic leukemia

## Select Publications

Barlogie B et al. **Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3.** *Br J Haematol* 2007;138(2):176-85. **Abstract**

Cheson BD. **Hematology: Rituximab for follicular lymphoma: Maintaining an open mind.** *Nat Rev Clin Oncol* 2011;8(5):257-8. **Abstract**

ECOG-E1411 — **Intergroup randomized Phase 2 four arm study in patients  $\geq$  60 with previously untreated mantle cell lymphoma of therapy with: arm A = rituximab + bendamustine followed by rituximab consolidation (RB  $\boxtimes$  R); arm B = rituximab + bendamustine + bortezomib followed by rituximab consolidation (RBV  $\rightarrow$  R), arm C = rituximab + bendamustine followed by lenalidomide + rituximab consolidation (RB  $\rightarrow$  LR) or arm D = rituximab + bendamustine + bortezomib followed by lenalidomide + rituximab consolidation (RBV  $\rightarrow$  LR).** NCT01415752

Fischer K et al. **Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.** *J Clin Oncol* 2011;29(26):3559-66. **Abstract**

Foyil KV, Barlett NL. **Brentuximab vedotin for the treatment of CD30+ lymphomas.** *Immunotherapy* 2011;3(4):475-85. **Abstract**

Friedberg JW et al. **The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.** *Blood* 2011;117(10):2807-12. **Abstract**

Geisler CH. **Front-line treatment of mantle cell lymphoma.** *Haematologica* 2010;95(8):1241-3. **Abstract**

Hoellenriegel J et al. **The phosphoinositide 3'kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.** *Blood* 2011;118(13):3603-12. **Abstract**

Lin TS. **New agents in chronic lymphocytic leukemia.** *Curr Hematol Malign Rep* 2010;5(1):29-34. **Abstract**

Parikh SA et al. **Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.** *Blood* 2011;118(8):2062-8. **Abstract**

Parker TL, Strout MP. **Chronic lymphocytic leukemia: Prognostic factors and impact on treatment.** *Discov Med* 2011;11(57):115-23. **Abstract**

Rajkumar SV et al. **Diagnosis of smoldering multiple myeloma.** *N Engl J Med* 2011;365(5):474-5. **Abstract**

Van Oers MH. **Rituximab maintenance therapy: A step forward in follicular lymphoma.** *Haematologica* 2007;92(6):826-33. **Abstract**

Wierda WG et al. **Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.** *J Clin Oncol* 2010;28(10):1749-55. **Abstract**

Yamamoto S et al. **Gastrointestinal follicular lymphoma: Review of the literature.** *J Gastroenterol* 2010;45(4):370-88. **Abstract**